Penalty Amount
$469,000,000
Colorado joined a 43-state-and-territory settlement resolving allegations that Sandoz and Fougera participated in a long-running conspiracy to inflate generic drug prices, reduce competition, and restrain trade. The companies agreed to pay approximately $469 million and implement reforms; the states are seeking court approval.
Sandoz agreed to pay approximately $469 million to settle the states’ claims and to implement reforms intended to ensure fair competition and compliance with antitrust laws. Eligible consumers may seek compensation for qualifying generic-drug purchases.
Review supplier, manufacturing, distribution, and customer agreements for provisions that could facilitate coordinated pricing or restrict competition, including exclusivity, pricing controls, information-sharing, market-allocation, and restrictions on competing products. Vendor and affiliate agreements should clearly allocate antitrust compliance obligations, extend those obligations to relevant affiliates and subcontractors, and provide audit, cooperation, and termination rights for suspected misconduct. This action concerns antitrust allegations rather than privacy practices, so it does not itself indicate a need to revise privacy, data-processing, or breach-notification clauses.
Entity
Sandoz Inc. and Fougera Pharmaceuticals Inc.
Industry
HealthcareOfficial Press Release
https://coag.gov/press-releases/colorado-slated-to-receive-2-1m-from-nationwide-settlement-with-sandoz-over-illegal-generic-drug-price-hikes-and-collusion/
10.1.26 Sandoz
https://coag.gov/app/uploads/2026/10/10.1.26-Sandoz.pdf
Colorado Attorney General Enforcement Page
https://coag.gov/
"with Sandoz Inc. and Fougera Pharmaceuticals Inc."
"Under the terms of this agreement, Sandoz will pay a total of approximately $469 million to settle the claims brought by the states."
"compliance with antitrust laws."
"engaged in a widespread, long-running conspiracy to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade"
$400.0M
New York Attorney General Letitia James and a coalition of 47 other attorneys general secured a $400 million settlement with Sandoz Inc. and Fougera Pharmaceuticals Inc. over an alleged scheme to coordinate generic drug prices and reduce competition. The settlement provides for consumer compensation and requires Sandoz to implement antitrust compliance reforms, including annual staff training and a Chief Compliance Officer.
$400.0M
Connecticut Attorney General William Tong announced a $400 million settlement with Sandoz Inc. and Fougera Pharmaceuticals Inc. resolving allegations that the generic drug manufacturers conspired to inflate prices, limit competition, and restrain trade. The settlement includes consumer restitution and injunctive reforms; court approval was being sought.
Colorado Attorney General Phil Weiser led a multistate coalition in filing a notice in Character Technologies, Inc.’s bankruptcy, citing concerns about the company’s safety and privacy practices and sensitive chatbot conversations involving children and adults. The filing seeks protections in any sale or transfer of the company’s business or assets; no penalty or final remedy is reported.
Colorado Attorney General Phil Weiser issued a public advisory explaining that e-bikes must meet statutory class requirements and that retailers must clearly disclose what they are selling. The advisory warns that marketing a higher-powered electric vehicle as an e-bike without required disclosures may violate state consumer protection law; it announces no penalty or binding remedy.
Colorado Attorney General Phil Weiser and a multistate coalition sued the U.S. Department of Labor over its termination of grants for unemployment insurance system improvements. The states allege the terminations breached their grant agreements and seek money damages; the release does not describe a privacy violation or an imposed penalty.
Colorado Attorney General Phil Weiser joined a multistate coalition in a comment letter opposing HHS’s proposed cuts to Head Start standards. The letter argues the changes could reduce protections and services for children and families; it is an advocacy action, not an enforcement action imposing a penalty or remedy.